Current pharmacotherapy for treating pediatric nonalcoholic fatty liver disease

Corte, Claudia Della; Liccardo, Daniela; Ferrari, Federica; Alisi, Anna; Nobili, Valério

doi:10.1517/14656566.2014.960389

Cited by 8 publications

(3 citation statements)

References 84 publications

(52 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Further validation of TE is necessary before it can be routinely adopted for the evaluation of NAFLD in childhood [14,15]. Novel therapeutic strategies have been tested in the last years with interesting results [16]. The drugs initially used in treatment of NAFLD, such as anti-oxidants (vitamin E), insulin-sensitizing (metformin) and cytoprotective agents (ursodeoxycholic acid -UDCA) have given disappointing results, with only limited effects, and, therefore, to date there is no definitive treatment for pediatric NAFLD.…”

Section: Nafldmentioning

confidence: 99%

Pediatric liver diseases: current challenges and future perspectives

Corte

Mosca

Vania

et al. 2015

Expert Review of Gastroenterology & Hepatology

Self Cite

View full text Add to dashboard Cite

Chronic liver diseases in children represent a rising problem with significant effects on public health. In fact, several pediatric liver diseases are precursors of adult chronic hepatopathies, cirrhosis and hepatocellular carcinoma. The prevalence of liver diseases in children is unknown. In the USA, every year, 15,000 children are hospitalized for liver diseases, but these disorders continue to be under-recognized or diagnosed late. The main reason is due to the frequent absence of symptoms in the vast majority of liver diseases, especially in the early stages. In the last few decades several advances have been made in understanding the pathogenesis of liver diseases, permitting the discovery of new therapeutic targets to treat liver diseases, thus improving the natural history of these disorders. In this article we discuss the most recent advances in the understanding of the pathogenesis, diagnosis and treatment of the most frequent pediatric liver diseases.

show abstract

Section: Nafldmentioning

confidence: 99%

Pediatric liver diseases: current challenges and future perspectives

Corte

Mosca

Vania

et al. 2015

Expert Review of Gastroenterology & Hepatology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Unfortunately, DHA showed no effect on liver fibrosis, with amelioration of steatosis, ballooning and lobular inflammation. Based on these promising results and the optimal safety profile, DHA represents a useful option in the treatment of pediatric NAFLD (4).…”

mentioning

confidence: 99%

“…The data available for pediatric NAFLD suggested that probiotics warrant consideration as an additional beneficial therapy in these patients, demonstrating a positive effect on echographic liver steatosis, amino- transferases serum levels and BMI; in addition, a positive effects on markers of inflammation and metabolic parameters, as cholesterol-low density lipoprotein (LDL) and insulin-resistance, were reported in adults treated with a mixture of probiotics (4). Based on the advances in pathogenetic mechanisms of NAFLD/NASH, several molecular pathways have been identified as possible targets of novel treatment for NAFLD.…”

mentioning

confidence: 99%